Bank of America Cuts RxSight (NASDAQ:RXST) Price Target to $6.50

Posted by Geri Gentry on Jul 7th, 2026

RxSight (NASDAQ:RXST – Get Free Report) had its price objective decreased by Bank of America from $8.00 to $6.50 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an “underperform” rating on the stock. Bank of America‘s price objective indicates a potential upside of 23.48% from the company’s previous close.

RXST has been the subject of several other research reports. Stifel Nicolaus cut their target price on RxSight from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Monday, March 9th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of RxSight in a report on Tuesday. Weiss Ratings downgraded RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Finally, Wells Fargo & Company cut their price objective on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, RxSight presently has a consensus rating of “Reduce” and a consensus target price of $9.17.

Read Our Latest Stock Analysis on RxSight

RxSight Stock Performance

Shares of RxSight stock traded down $0.34 during trading hours on Tuesday, hitting $5.26. The company’s stock had a trading volume of 1,522,591 shares, compared to its average volume of 972,348. The business has a 50 day moving average price of $5.58 and a two-hundred day moving average price of $7.46. RxSight has a 12-month low of $4.48 and a 12-month high of $13.22. The company has a market cap of $217.93 million, a PE ratio of -4.64 and a beta of 1.15.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of RxSight in the second quarter worth about $28,000. Summit Securities Group LLC bought a new position in RxSight during the first quarter valued at approximately $30,000. Larson Financial Group LLC grew its holdings in RxSight by 110.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in RxSight by 440.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after buying an additional 3,063 shares in the last quarter. Finally, CWM LLC increased its stake in RxSight by 211.1% in the 4th quarter. CWM LLC now owns 3,826 shares of the company’s stock worth $40,000 after acquiring an additional 2,596 shares during the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

(Get Free Report)

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.